tetano
Editor, Senior Moderator
Environ Health Insights
. 2022 Oct 20;16:11786302221129396.
doi: 10.1177/11786302221129396. eCollection 2022.
Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
Smaranika Rahman[SUP] 1 [/SUP], Md Jamal Hossain[SUP] 2 [/SUP], Zabun Nahar[SUP] 1 [/SUP], Mohammad Shahriar[SUP] 1 [/SUP], Mohiuddin Ahmed Bhuiyan[SUP] 1 [/SUP], Md Rabiul Islam[SUP] 1 [/SUP]
Affiliations
Abstract
The COVID-19 pandemic has become the most devastating pandemic of the 21st century since its appearance in December 2019. Like other RNA viruses, continuous mutation is common for coronavirus to create several variants and subvariants. The main reason behind this mutation and evolvement of SARS-CoV-2 was its structural spike (S) glycoprotein. Coronavirus has become a threat to global public health due to its high mutation capability and antibody neutralizing capacity. According to the World Health Organization (WHO), there are 5 major variants of concern (VOC) are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Recently, different Omicron subvariants have gained worldwide dominance, such as BA.1, BA.2, BA.3, BA.4, and BA.5. However, there is a discernible drop in this symptomatic sickness globally due to the success of numerous monoclonal antibodies and vaccinations. Here we also discussed the currently dominant Omicron subvariants and the effectiveness of antiviral agents and vaccines. Based on the available data and our knowledge, we can suggest that the global healthcare organizations can decide on the declaration of the end of the pandemic phase of COVID-19 soon; however, the covid-19 will continue.
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 subvariants; public health.
. 2022 Oct 20;16:11786302221129396.
doi: 10.1177/11786302221129396. eCollection 2022.
Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
Smaranika Rahman[SUP] 1 [/SUP], Md Jamal Hossain[SUP] 2 [/SUP], Zabun Nahar[SUP] 1 [/SUP], Mohammad Shahriar[SUP] 1 [/SUP], Mohiuddin Ahmed Bhuiyan[SUP] 1 [/SUP], Md Rabiul Islam[SUP] 1 [/SUP]
Affiliations
- PMID: 36299441
- PMCID: PMC9585367
- DOI: 10.1177/11786302221129396
Abstract
The COVID-19 pandemic has become the most devastating pandemic of the 21st century since its appearance in December 2019. Like other RNA viruses, continuous mutation is common for coronavirus to create several variants and subvariants. The main reason behind this mutation and evolvement of SARS-CoV-2 was its structural spike (S) glycoprotein. Coronavirus has become a threat to global public health due to its high mutation capability and antibody neutralizing capacity. According to the World Health Organization (WHO), there are 5 major variants of concern (VOC) are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Recently, different Omicron subvariants have gained worldwide dominance, such as BA.1, BA.2, BA.3, BA.4, and BA.5. However, there is a discernible drop in this symptomatic sickness globally due to the success of numerous monoclonal antibodies and vaccinations. Here we also discussed the currently dominant Omicron subvariants and the effectiveness of antiviral agents and vaccines. Based on the available data and our knowledge, we can suggest that the global healthcare organizations can decide on the declaration of the end of the pandemic phase of COVID-19 soon; however, the covid-19 will continue.
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 subvariants; public health.